Pharmacokinetics of mebendazole in plasma and cerebrospinal fluid following a single oral dose in healthy dogs.

Autor: Yanke AB; Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, United States., Day KE; Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; BluePearl Pet Hospital North Dallas, Lewisville, TX, United States., Taylor AR; Southeast Veterinary Neurology, Boynton Beach, FL, United States., Cruz-Espindola C; Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States., Boothe DM; Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
Jazyk: angličtina
Zdroj: Frontiers in veterinary science [Front Vet Sci] 2023 Aug 28; Vol. 10, pp. 1231769. Date of Electronic Publication: 2023 Aug 28 (Print Publication: 2023).
DOI: 10.3389/fvets.2023.1231769
Abstrakt: Novel therapies are needed for treatment of gliomas. Mebendazole previously demonstrated anti-neoplastic effects on canine glioma cell lines at in vitro mean inhibitory concentrations (IC 50 ) of 10 ng/mL. Our study aimed to titrate the oral dose of mebendazole necessary to achieve concentrations ≥10 ng/mL in cerebrospinal fluid (CSF) of healthy dogs. We hypothesized that an oral dose up to 200 mg/kg would be necessary. Phase one was a dose titration study using a total of 6 mixed breed dogs that described dose vs. plasma concentrations for 72 h after single oral dosing of either 50 mg/kg ( n  = 2), 100 mg/kg ( n  = 2), or 200 mg/kg ( n  = 2). Based on phase one, phase two dogs (total of 9) received 100 mg/kg ( n  = 4) or 200 mg/kg ( n  = 5) orally and blood samples were collected intermittently for 60 h with CSF samples collected intermittently for 24 h. Mebendazole was quantitated in plasma and CSF using high performance liquid chromatography. Median peak plasma concentrations (Cmax) were reached at 7 ± 2 h (100 mg/kg) of 220 ng/mL (81, 283) and at 15 ± 4 h (200 mg/kg) of 147 ng/ml (112, 298). The respective area under the curve (AUC: ng/ml/h) reported as a median was 2,119 (1,876, 3,288) vs. 3,115 (1,559, 4,972). Median plasma concentrations (ng/ml) for 100 vs. 200 mg/kg were 47 (32, 52) vs. 65 (35, 104), respectively. For CSF, the median value for Cmax (at 100 mg/kg vs. 200 mg/kg) was 8 (2, 28) vs. 21 (12, 27) and AUC was 87 (22, 157) vs. 345 (92, 372), respectively. Relative bioavailability in CSF vs. plasma was 4 to 10%. Although several animals demonstrated clinical signs indicative of gastrointestinal upset [i.e., vomiting ( n  = 2), diarrhea ( n  = 2), or both ( n  = 1)], these events were not considered serious. The in vitro IC 50 for gliomas can be reached in CSF at 100 mg/kg ( n  = 1), however a 200 mg/kg dose yielded more consistent concentrations.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor RB declared a past co-authorship with the author AY.
(Copyright © 2023 Yanke, Day, Taylor, Cruz-Espindola and Boothe.)
Databáze: MEDLINE
Externí odkaz: